Show simple item record

dc.contributor.authorRanson, Malcolm R
dc.contributor.authorCheeseman, Sue
dc.contributor.authorWhite, Shane C
dc.contributor.authorMargison, Jennifer M
dc.date.accessioned2009-10-12T16:43:56Z
dc.date.available2009-10-12T16:43:56Z
dc.date.issued2001-02
dc.identifier.citationCaelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. 2001, 37 (2):115-20 Crit. Rev. Oncol. Hematol.en
dc.identifier.issn1040-8428
dc.identifier.pmid11166584
dc.identifier.urihttp://hdl.handle.net/10541/84097
dc.description.abstractAnthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshBreast Neoplasms
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLiposomes
dc.titleCaelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research Campaign, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M204BX, UK. malcolm.ransom@man.ac.uken
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
html.description.abstractAnthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.


This item appears in the following Collection(s)

Show simple item record